Humana Inc.

(New York Stock Exchange)
Back to all articles
Bullish +55

Andra AP fonden Buys New Stake in Humana Inc. $HUM

AI-generated analysis

πŸ“ˆ Andra AP fonden purchased 2,082 shares of Humana Inc. valued at approximately $361,000 during the first quarter.

🏦 Montag A & Associates boosted holdings by 1,880% in Q4, while CoreCap Advisors increased its stake by 54.4%.

πŸ’° Humana reported quarterly EPS of $10.31, beating analyst estimates of $9.97 by $0.34.

πŸ“Š Revenue for the quarter reached $39.65 billion, marking a significant 23.5% increase year-over-year.

🎯 Royal Bank of Canada raised its price target to $415.00 and maintained a 'sector perform' rating.

πŸ“‰ The consensus analyst rating is currently 'Hold' with an average target price of $327.17.

πŸ“ˆ Humana's stock opened at $394.37, trading above its 50-day moving average of $362.43.

πŸ₯ The company maintains a debt-to-equity ratio of 0.66 and a current ratio of 1.77.

πŸ“… Humana has set FY 2026 EPS guidance between $9.00 and $9.46 per share.

πŸ‘΄ The insurer primarily serves seniors and Medicare-eligible populations across the United States.

Bullish Signals
  • Humana reported quarterly earnings of $10.31 per share, surpassing the consensus estimate of $9.97 by $0.34.
  • Revenue grew significantly by 23.5% year-over-year to reach $39.65 billion for the quarter.
  • Royal Bank of Canada increased its price target to $415.00, indicating strong institutional confidence in valuation.
  • Piper Sandler raised its price objective to $254.00 from a previous level of $182.00.
  • The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.66 and a current ratio of 1.77.
  • Stock price is trading above both its 50-day moving average ($362.43) and 200-day moving average ($264.14).
  • Multiple institutional investors, including Andra AP fonden and Montag A & Associates, have recently increased their stakes.
Risk Factors
  • The consensus analyst rating is currently 'Hold', suggesting analysts are cautious about immediate upside potential.
  • The stock trades at a high price-to-earnings ratio of 42.18, which may limit near-term appreciation if growth slows.
Full Analysis
Andra AP fonden increased its position in Humana Inc. (NYSE:HUM) during the first quarter by purchasing 2,082 shares valued at approximately $361,000. This move adds to a broader trend of institutional activity, with other firms like Montag A & Associates and CoreCap Advisors also adjusting their stakes in the health insurance provider. Analyst sentiment remains mixed but generally positive regarding valuation targets. Royal Bank of Canada raised its price target to $415.00, while Piper Sandler increased its objective to $254.00. The consensus average rating is currently a 'Hold' with a target price of $327.17, though the stock recently traded above these levels. Humana reported strong financial results for the quarter ended April 29th, posting earnings per share of $10.31 against a consensus estimate of $9.97. Revenue reached $39.65 billion, representing a 23.5% year-over-year increase. The company has set full-year 2026 guidance for EPS between $9.00 and $9.46. The Louisville-based insurer continues to focus on its core Medicare Advantage business and commercial plans. With a market capitalization of $47.35 billion and a P/E ratio of 42.18, the stock reflects investor expectations for continued growth in its senior-focused healthcare segment.